Monitoring Blood Pressure at Home and Pharmacy Telehealth (REMAP-BP)

REmote Blood Pressure Monitoring and Pharmacist-Led Telehealth Program in an Emergency Department Transitional Care Clinic

The overall goal of this project is to determine if measuring blood pressure at home and staying in contact with a team of pharmacists and physicians to manage participants' blood pressure is useful. The study will enroll 400 participants who are seen at the University of Alabama at Birmingham Emergency Department - Transitional Care Clinic and Tampa General Hospital -Transitional Care Clinic. Half of the participants (200 patients) will be asked to measure blood pressure at home, and half of the participants (200 patients) will continue to receive usual care. Participants who measure blood pressure at home will also meet with a pharmacist weekly over the phone to discuss blood pressure readings and have blood pressure medications prescribed if needed. This program will last 6 months.

Study Overview

• Status: Not yet recruiting
• Conditions: Hypertension; Blood Pressure
• Intervention / Treatment: Behavioral: Remote Blood Pressure Monitoring + Telehealth

Detailed Description

For all participants:

1. Participants will receive information on the importance of measuring blood pressure and ways to improve blood pressure.
2. Participants will complete questionnaires describing current socioeconomic position, medical history and healthcare needs.
3. Participants will come in for three research clinic visits to get blood pressure measured 3 months after enrollment in this study, and 6 months after enrollment in this study.

For participants asked to measure blood pressure at home:

1. Measure blood pressure twice a day at home, following the instructions provided. The study will provide participants with the device and send text message reminders each week day. Participants will return the device at study visit 3 months from now.
2. Following the instructions provided, participants will talk to a pharmacist over the phone weekly to discuss blood pressure and medications. All medication changes will be discussed with a collaborating physician.
3. Participants will complete questionnaires and interviews on satisfaction with the program.

• Study Type: Interventional
• Enrollment (Estimated): 420
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Bernadette Johnson; Phone Number: 205-934-7329; Email: bajohnson@uabmc.edu
• Study Contact Backup: Name: Tammi Thomas; Phone Number: 205-934-7839; Email: tammithomas@uabmc.edu

Study Locations

• United States
  • Alabama
    • Birmingham, Alabama, United States, 35233
      • University of Alabama at Birmingham
      • Contact: Bernadette Johnson; Phone Number: 205-934-7329; Email: bajohnson@uabmc.edu
      • Contact: Tammi Thomas; Phone Number: 205-934-7839; Email: tammithomas@uabmc.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Age ≥18 years
• Ability to speak English
• Seen at UAB's or TGH's Emergency Department-Transitional Care Clinic
• Blood pressure at Emergency Department-Transitional Care Clinic: Systolic BP ≥ 130 mmHg or Diastolic BP ≥ 80 mmHg
• Have a cellphone with video capability

Exclusion Criteria:

• Systolic BP ≥ 160 mmHg or Diastolic BP ≥ 100 mmHg (i.e. severe range hypertension (HTN) by the 2025 American College of Cardiology/American Heart Association BP guidelines) as they typically are referred to immediate treatment intensification. Since the prevalence of severe HTN is low (i.e.<5%) in the US population, exclusion of these individuals will have only a small effect on the study.)
• Lack of willingness or inability to provide written informed consent
• Individuals who work overnight or second shift
• History of known major arrhythmias
• Currently pregnant or breastfeeding
• Arm circumference >50 cm. *The upper limit for the largest BP cuff for oscillometric BP devices is typically 50-52 cm; data from the National Health and Nutrition Examination Survey, 2011-2016 indicated that <1% of US adults have an arm circumference >50 cm, so this will have minimal effect on our study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Remote Blood Pressure Monitoring + Telehealth; Participants will undergo remote blood pressure monitoring and pharmacist led telehealth intervention for blood pressure management	Behavioral: Remote Blood Pressure Monitoring + Telehealth; Participants will undergo remote blood pressure monitoring and pharmacist led telehealth intervention for blood pressure management
No Intervention: Usual Care; Participants receive usual care from providers to manage blood pressure

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Total Number of Enrolled Participants with Blood Pressure Control	The number of enrolled participants with blood pressure control	12 weeks (3 months) from randomization

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants in the Intervention with Patient-Reported Outcomes	The number of participants with completed qualitative interviews and surveys regarding intervention adherence and satisfaction. The survey will assess intervention adherence and satisfaction using the following scales: Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), and the Feasibility of Intervention Measure (FIM). The AIM is a 4-item scale where the min. value per item is 1 and the max. value per item is 5. A higher total score indicates better acceptability while the lower total score indicates worse acceptability. The IAM is a 4-item scale where the min. value per item is 1 and the max. value per item is 5. A higher total score indicates better appropriateness while the lower total score indicates worse appropriateness. The FIM is a 4-item scale where the min. value per item is 1 and the max. value per item is 5. A higher total score indicates better feasibility while the lower total score indicates worse feasibility.	24 weeks (6 months) from randomization

Collaborators and Investigators

• Sponsor: University of Alabama at Birmingham
• Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
• Investigators: Principal Investigator: Lama Ghazi, MD, PhD, University of Alabama at Birmingham

Study record dates

Study Major Dates

• Study Start (Estimated): April 1, 2027
• Primary Completion (Estimated): January 1, 2031
• Study Completion (Estimated): January 1, 2031

Study Registration Dates

• First Submitted: May 28, 2026
• First Submitted That Met QC Criteria: May 28, 2026
• First Posted (Actual): June 3, 2026

Study Record Updates

• Last Update Posted (Actual): June 15, 2026
• Last Update Submitted That Met QC Criteria: June 11, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Keywords: Telemedicine; Vascular Diseases; Cardiovascular Diseases; Delivery of Health Care; Patient Care Management; Health Services Administration
• Additional Relevant MeSH Terms: Hypertension; Cardiovascular Diseases; Vascular Diseases; Health Services Administration; Delivery of Health Care; Patient Care Management; Telemedicine
• Other Study ID Numbers: IRB-300016615; National Heart, Lung, & Blood (Other Identifier: National Heart, Lung, and Blood Institute (NHLBI))

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: While the investigators do not anticipate generating research tools, the investigators are committed to adhering to the National Institutes of Health (NIH) Research Tools Policy to ensure that any resources developed under this award are readily available to qualified researchers. If an NIH-defined research tool is developed, the investigators will collaborate with University of Alabama at Birmingham Commercialization and Licensing Office and all participating institutions to define ownership, protect intellectual property, and establish a dissemination strategy that ensures appropriate access and compliance with NIH guidelines.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No